Metronomics and low/middle income countries, especially in breast cancer

Continual low-dose metronomic chemotherapy as potentially preferable to aggressive strategies

Drug repurposing as an alternative to costly drugs such as herceptin in breast cancer

Benefits of metronomic chemotherapy and the aims of the Metronomic Global Health Initiative

Cost-effectiveness of metronomic approach to neuroblastoma and its use in combination with other therapies

New metronomic approach to neuroblastoma

WIN consortium as a basis for forming cross-border collaborations for improving personalised medicine and palliative care

Tumour-infiltrating immune cells as classifiers and predictors of outcome

Retinoic acid in acute promyelocytic leukaemia as alternative to chemotherapy

Advances in chronic lymphocytic leukaemia: Expert panel discussion

Investigating anticarcinogenic compounds as an alternative to chemo

ASCO 2014 roundup